-transparent.png){kind=logo}
Somatostatin-like immunoreactivity (SLI) and neuropeptide Y-like immunoreactivity (NPYLI) were measured in postmortem brain tissue from 12 control patients and 13 demented Parkinsonian patients who had Alzheimer-type cortical pathology. Twenty-two cortical regions were examined. Significant reductions in cortical SLI were found in 17 regions, while significant reductions in cortical NPYLI were found in nine regions. The reductions in SLI were typically 50-60%, while NPYLI reductions were 20-30%. These findings are similar to those in Alzheimer's disease (AD) and are consistent with a previous report of a dissociation between reductions in SLI and NPYLI in Parkinson's disease (PD) with dementia.
M F Beal, and
R A Clevens, and
M F Mazurek
November 1986,
Brain research,
M F Beal, and
R A Clevens, and
M F Mazurek
June 1985,
Brain research,
M F Beal, and
R A Clevens, and
M F Mazurek
December 1990,
Journal of neurology, neurosurgery, and psychiatry,
M F Beal, and
R A Clevens, and
M F Mazurek
September 1986,
Neuroscience letters,
M F Beal, and
R A Clevens, and
M F Mazurek
January 1985,
Biochemical and biophysical research communications,
M F Beal, and
R A Clevens, and
M F Mazurek
December 2001,
Peptides,
M F Beal, and
R A Clevens, and
M F Mazurek
January 1997,
Dementia and geriatric cognitive disorders,
M F Beal, and
R A Clevens, and
M F Mazurek
September 1986,
Annals of neurology,
M F Beal, and
R A Clevens, and
M F Mazurek
April 1986,
Brain research,
M F Beal, and
R A Clevens, and
M F Mazurek
June 1996,
Naunyn-Schmiedeberg's archives of pharmacology,
